Why atrial fibrillation duration should be an endpoint in atrial fibrillation ablation trials

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Professor Madelene Carina Blomstrom-Lundqvist

Orebro University Hospital, Orebro (Sweden)

4 More presentations in this session

Presentation thumbnail

The three pillars of atrial fibrillation management

Professor G. Lip (Liverpool, GB)

Presentation thumbnail

Will left atrial appendage occlusion replace oral anticoagulation?

Professor M. Glikson (Jerusalem, IL)

Presentation thumbnail

Pulsed field ablation: should it replace radiofrequency and balloon cryoablation?

Doctor T. De Potter (Aalst, BE)

Presentation thumbnail

Management of atrial fibrillation: knowns and unknowns - discussion

Access the full session

Session thumbnail

Management of atrial fibrillation: knowns and unknowns

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

Atrial fibrillation burden as efficacy endpoint for atrial fibrillation ablation: strengths and weaknesses of implementation

Congress Presentation

Evolving concepts in atrial fibrillation: classification, burden, and key trial endpoints

Congress Presentation

Clinical implications of atrial fibrillation recurrence vs. burden following catheter ablation: outcome data from 3 contemporary clinical trials using an insertable cardiac monitor

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources